Overview

• Presented at ESC 2025 and published in NEJM, baxdrostat 1 mg and 2 mg achieved placebo‑adjusted systolic reductions of −8.7 mmHg and −9.8 mmHg at 12 weeks (both p6 mmol/L, and no adrenocortical insufficiency reported.
• Baxdrostat inhibits aldosterone synthesis, with exploratory 24‑hour ambulatory systolic reductions of −16.9 mmHg at 12 weeks; an open‑label safety follow‑up to week 52 is ongoing.